title: Elevated intakes of supplemental chromium improve glucose and insulin variables in individuals with type 2 diabetes.
abstract: Chromium is an essential nutrient involved in normal carbohydrate and lipid metabolism. The chromium requirement is postulated to increase with increased glucose intolerance and diabetes. The objective of this study was to test the hypothesis that the elevated intake of supplemental chromium is involved in the control of type 2 diabetes. Individuals being treated for type 2 diabetes (180 men and women) were divided randomly into three groups and supplemented with: 1) placebo, 2) 1.92 micromol (100 microg) Cr as chromium picolinate two times per day, or 3) 9.6 micromol (500 microg) Cr two times per day. Subjects continued to take their normal medications and were instructed not to change their normal eating and living habits. HbA1c values improved significantly after 2 months in the group receiving 19.2 pmol (1,000 microg) Cr per day and was lower in both chromium groups after 4 months (placebo, 8.5 +/- 0.2%; 3.85 micromol Cr, 7.5 +/- 0.2%; 19.2 micromol Cr, 6.6 +/- 0.1%). Fasting glucose was lower in the 19.2-micromol group after 2 and 4 months (4-month values: placebo, 8.8 +/- 0.3 mmol/l; 19.2 micromol Cr, 7.1 +/- 0.2 mmol/l). Two-hour glucose values were also significantly lower for the subjects consuming 19.2 micromol supplemental Cr after both 2 and 4 months (4-month values: placebo, 12.3 +/- 0.4 mmo/l; 19.2 micromol Cr, 10.5 +/- 0.2 mmol/l). Fasting and 2-h insulin values decreased significantly in both groups receiving supplemental chromium after 2 and 4 months. Plasma total cholesterol also decreased after 4 months in the subjects receiving 19.2 micromol/day Cr. These data demonstrate that supplemental chromium had significant beneficial effects on HbA1c, glucose, insulin, and cholesterol variables in subjects with type 2 diabetes. The beneficial effects of chromium in individuals with diabetes were observed at levels higher than the upper limit of the Estimated Safe and Adequate Daily Dietary Intake.
authors.affiliation: Beltsville Human Nutrition Research Center, U.S. Department of Agriculture, Maryland 20705-2350, USA. anderson@307.bhnrc.usda.gov
authors.forename: R A
authors.initials: RA
authors.lastname: Anderson
authors.forename: N
authors.initials: N
authors.lastname: Cheng
authors.forename: N A
authors.initials: NA
authors.lastname: Bryden
authors.forename: M M
authors.initials: MM
authors.lastname: Polansky
authors.forename: N
authors.initials: N
authors.lastname: Cheng
authors.forename: J
authors.initials: J
authors.lastname: Chi
authors.forename: J
authors.initials: J
authors.lastname: Feng
mesh_terms: D000328:Adult; D000368:Aged; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism*; D002857:Chromium / Q000627:therapeutic use*; D003924:Diabetes Mellitus, Type 2 / Q000097:blood* / Q000188:drug therapy*; D005215:Fasting; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007328:Insulin / Q000097:blood* / Q000378:metabolism; D000078790:Insulin Secretion; D008297:Male; D008875:Middle Aged; D010848:Picolinic Acids / Q000627:therapeutic use; D010919:Placebos; D019518:Postprandial Period
chemical_list: D001786:Blood Glucose; D002857:Chromium; D006442:Glycated Hemoglobin; D007328:Insulin; D010848:Picolinic Acids; D010919:Placebos; C030614:picolinic acid